AMNIO TECHNOLOGY

Amnio Technology Launches Two New Dual-Layer Allografts, FDA Recognizes Products as Minimally Manipulated, Homologous Use HCT/Ps

Retrieved on: 
Monday, February 14, 2022
Wound healing, Regulation, Motivation, GTP, Patient, Technology, Family, Quality of life, Company, Science, Good tissue practice, Team, Doctor of Philosophy, Cytokine, Standard of care, Matrix, Scientist, Compliance, Regenerative medicine, FDA, Burns, TRG, Allotransplantation, New product development, Multimedia, CFR, Extracellular matrix, Agency, Medicine, Medical imaging, Pharmaceutical industry, Tissue

The new allografts, like the entire family of PalinGen membrane products, are minimally manipulated, homologous use and chorion-free.

Key Points: 
  • The new allografts, like the entire family of PalinGen membrane products, are minimally manipulated, homologous use and chorion-free.
  • The proprietary Advantek process used to manufacture PalinGen membranes preserves the extracellular matrix components and regulatory proteins present in amniotic tissues.
  • The FDA recognized PalinGen Dual-Layer Membrane and Dual Layer PalinGen X-Membrane as being minimally manipulated, homologous use human cell, tissue, and cellular and tissue-based products or HCT/Ps.
  • For more information about Amnio Technology, please visit the Company website at www.amniotechnology.com .

Amnio Technology Awarded U.S. Patent for Amniotic Allografts

Retrieved on: 
Friday, September 24, 2021
Technology, Patent, Regenerative medicine, Good tissue practice, Multimedia, United States Patent and Trademark Office, Company, European Union, LLC, Science, New product development, Union, Research, Investment, Intellectual property, Doctor of Philosophy, Pharmaceutical industry

PHOENIX, Sept. 23, 2021 /PRNewswire/ -- Amnio Technology, LLC, a global leader in the development and distribution of amniotic tissue allografts, is announcing today that the United States Patent and Trademark Office has issued a new patent titled, "Enriched Multilayer Amnion Derived Tissue Graft."

Key Points: 
  • PHOENIX, Sept. 23, 2021 /PRNewswire/ -- Amnio Technology, LLC, a global leader in the development and distribution of amniotic tissue allografts, is announcing today that the United States Patent and Trademark Office has issued a new patent titled, "Enriched Multilayer Amnion Derived Tissue Graft."
  • The new patent strengthens Amnio Technology's intellectual property position by further protecting its advanced allograft manufacturing processes in the United States.
  • "This newest patent issuance highlights the investments Amnio Technology has made in the areas of human tissue-based product manufacturing excellence and clinical utility" said Senior Director of New Product Development, Rob Diller, PhD.
  • Established in 2013, Amnio Technology has developed core competencies in Good Tissue Practice and HCT/P Safety becoming a global leader in the development and distribution of amniotic tissue allografts.